GCIA
DMAAR

Gabelli & Co Investment Advisers’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.9K Buy
+48,100
New +$5.09K ﹤0.01% 290

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Gabelli & Co Investment Advisers's DMAAR Position: Q1 2026 in Review

Gabelli & Co Investment Advisers opened a new position in Drugs Made In America Acquisition Corp Rights (DMAAR) in Q1 2026: 48,100 shares worth $2.9K. The stake represents ﹤0.01% of the portfolio and ranks #290 among its holdings.

35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

  • Gabelli & Co Investment Advisers held 48,100 shares of Drugs Made In America Acquisition Corp Rights worth $2.9K as of Q1 2026.
  • Drugs Made In America Acquisition Corp Rights was a new Gabelli & Co Investment Advisers position in Q1 2026.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Gabelli & Co Investment Advisers's portfolio in Q1 2026, its #290 holding.
  • 35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.